The contractor shall evaluate compounds for anticancer activity in experimental in vivo tumor models. Studies shall focus on agents identified by the Program's disease-oriented in vitro drug screen, and shall employ human tumors growing in immune-deficient mice. Experiments shall be designed and conducted to optimize drug activity, and evaluate the drug's therapeutic potential.
| Marcantonio, D; Panasci, L C; Hollingshead, M G et al. (1997) 2-Chloroethyl-3-sarcosinamide-1-nitrosourea, a novel chloroethylnitrosourea analogue with enhanced antitumor activity against human glioma xenografts. Cancer Res 57:3895-8 |
